Is More M&A On The Way For Large-Cap Biotechs?

Following the recently-announced Teva Pharmaceutical TEVA 2.55% buyout of Allergan Plc AGN 2.7%, RBC Capital Markets analyst Michael Yee released a report discussing the potential for large-cap biotech companies to become buyout targets for specialty pharmaceutical companies. According to Yee, no such deal would even be feasible until “well into 2016.”


Internet Penetration In China Remains Below 50%

The latest report from the China Internet Network Information Center (CNNIC) includes some truly staggering statistics involving the growth potential for Internet usage in China. It may come as no surprise that the number of Internet users in China dwarfs the number of users in the United States. However, there are currently still 700 million…

1 Alpha Opportunity In The Current S&P Skew

In a new report, Bank of America analyst Youssef Brahimi discusses how traders can profit from the extremely narrow trading range and steep skew that the S&P 500 has exhibited throughout 2015. Brahimi suggests one approach to the historically tight trading range using an SPX option strategy.